Rostab EZ Tablet 10 mg+10 mg is a fixed-dose combination containing Rosuvastatin Calcium 10 mg and Ezetimibe 10 mg, designed for the treatment of hypercholesterolemia and mixed dyslipidemia in adults. This higher-strength formulation is intended for patients who require enhanced LDL cholesterol reduction beyond what is achieved with monotherapy.
Rosuvastatin, a statin, works by inhibiting cholesterol synthesis in the liver, while Ezetimibe selectively blocks cholesterol absorption in the intestine. Together, they produce a synergistic effect to significantly lower LDL cholesterol and total cholesterol, moderately reduce triglycerides, and slightly increase HDL cholesterol. This combination is particularly effective for patients at high cardiovascular risk or those with familial hypercholesterolemia, providing comprehensive lipid management and reducing the likelihood of heart attack, stroke, or other atherosclerotic events.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Each tablet contains:
Rosuvastatin Calcium 10 mg
Ezetimibe 10 mg
Excipients: Microcrystalline cellulose, lactose, magnesium stearate, and other standard tablet excipients
Rostab EZ Tablet 10 mg+10 mg is indicated for:
Primary hypercholesterolemia to lower LDL cholesterol and total cholesterol
Mixed dyslipidemia with elevated triglycerides and LDL cholesterol
Familial hypercholesterolemia as adjunct therapy with diet modification
Adults who need intensive lipid-lowering therapy when statin monotherapy is insufficient
Prevention of cardiovascular events in patients at high risk of heart disease or stroke
The combination of Rosuvastatin and Ezetimibe in Rostab EZ provides dual action:
Rosuvastatin Calcium:
Inhibits HMG-CoA reductase, reducing cholesterol production in the liver
Lowers LDL cholesterol and triglycerides while modestly raising HDL cholesterol
Improves endothelial function and stabilizes atherosclerotic plaques
Ezetimibe:
Blocks intestinal cholesterol absorption at the brush border
Reduces the amount of cholesterol delivered to the liver
Provides additive LDL-lowering when combined with Rosuvastatin
This dual mechanism ensures greater efficacy in lowering cholesterol than either component alone.
Adults: 1 tablet once daily, with or without food
Take at the same time each day, preferably in the evening, when hepatic cholesterol synthesis is highest
Continue dietary modifications, regular exercise, and lifestyle measures alongside the medication
Monitor lipid levels, liver function tests, and kidney function periodically
Dose adjustment may be considered based on response and tolerability
Avoid use in patients with active liver disease or persistent elevations in liver enzymes
Use cautiously in patients with renal impairment or a history of muscle disorders
Inform your physician about all medications to avoid drug interactions, particularly CYP3A4 inhibitors
Not recommended during pregnancy or breastfeeding
Seek immediate medical attention for unexplained muscle pain, weakness, or tenderness
Rostab EZ Tablet 10 mg+10 mg is generally well tolerated. Possible side effects include:
Headache
Gastrointestinal discomfort (nausea, abdominal pain)
Muscle pain or mild weakness
Temporary elevation of liver enzymes
Rarely, serious muscle injury (rhabdomyolysis)
Most side effects are mild, transient, and resolve with dose adjustment or discontinuation under medical supervision.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Store below 30°C in a cool, dry place
Protect from light and moisture
Keep out of reach of children
Rostab EZ Tablet 10 mg+10 mg (Rosuvastatin + Ezetimibe) is an effective combination therapy for adults who require intensive cholesterol management. By targeting both cholesterol synthesis and absorption, it lowers LDL cholesterol, reduces triglycerides, and supports cardiovascular risk reduction. When used with lifestyle modifications, this tablet provides a safe, convenient, and comprehensive approach to managing hypercholesterolemia and mixed dyslipidemia.
Login Or Registerto submit your questions to seller
No none asked to seller yet